




RealRate

PHARMACEUTICAL 2022

NovaBay Pharmaceuticals Inc.
Rank 302 of 466



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 73% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is 62%, being 16% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	13,170
Cost of Goods Sold	2,776
Intangible Assets	9,728
Liabilities, Current	3,442
Liabilities, Non-Current	246
Other Assets	887
Other Compr. Net Income	0
Other Expenses	2,608
Other Liabilities	10,119
Other Net Income	-1,577
Other Revenues	8,421
Property and Equipment	193
Research and Development	44
Selling, General and Administrative Expense	7,240

Output Variable	Value in 1000 USD
Assets	23,978
Liabilities	13,807
Expenses	12,668
Revenues	8,421
Stockholders Equity	10,171
Net Income	-5,824
Comprehensive Net Income	-5,824
Economic Capital Ratio	62%